Cullinan Oncology LLC
$ 14.27
2.00%
24 Feb - close price
- Market Cap 843,018,000 USD
- Current Price $ 14.27
- High / Low $ 14.56 / 13.88
- Stock P/E N/A
- Book Value 7.64
- EPS -3.32
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.40 %
- 52 Week High 14.56
- 52 Week Low 5.68
About
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$30.63
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-15 | 2024-03-14 | 2023-11-08 | 2023-08-10 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.77 | -1.19 | -0.74 | -0.73 | -0.69 | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 | -1.42 | -0.59 |
| Estimated EPS | -0.95 | -0.82 | -0.99 | -0.7423 | -0.81 | -0.73 | -0.99 | -0.96 | -0.92 | -0.97 | -0.98 | -0.66 |
| Surprise | 0.18 | -0.37 | 0.25 | 0.0123 | 0.12 | -0.02 | 0.13 | 0.42 | 0.01 | 0.15 | -0.44 | 0.07 |
| Surprise Percentage | 18.9474% | -45.122% | 25.2525% | 1.657% | 14.8148% | -2.7397% | 13.1313% | 43.75% | 1.087% | 15.4639% | -44.898% | 10.6061% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.8 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CGEM
2026-02-23 20:46:28
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models, highlighting strong sentiment across all time horizons supporting an overweight bias despite elevated downside risk and no clear price positioning signal. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points. The analysis includes multi-timeframe signal strengths and support/resistance levels generated by AI for informed trading decisions.
2026-02-20 01:03:53
Cullinan Therapeutics executives have identified 2026 as a "defining year" due to anticipated catalysts from their T-cell engager programs, CLN-978 and CLN-049, and updates on their partnered EGFR exon 20 inhibitor, zipalertinib. The company reported over $430 million in cash, providing runway into 2029, and is pushing for first-in-class or best-in-class therapies in oncology and autoimmune diseases. Key developments include promising early AML activity for CLN‑049, advancing CLN‑978 for autoimmune diseases, and Taiho's near-complete rolling NDA submission for zipalertinib.
2026-02-18 18:57:34
Cullinan Therapeutics, Inc. announced that its CEO, Nadim Ahmed, and CMO, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026. The biopharmaceutical company focuses on developing therapies for autoimmune diseases and cancer. A webcast of the chat will be available on the company's investor relations website.
2026-02-18 12:28:23
Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, at 10:00 a.m. ET. The clinical-stage biopharmaceutical company focuses on developing therapies for autoimmune diseases and cancer. A webcast of their discussion will be available on the company's investor relations website.
2026-02-18 07:00:00
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit. The event is scheduled for Thursday, February 19, 2026, at 10:00 a.m. ET. A webcast will be available on the company's investor relations website for those interested.
2026-02-13 07:27:17
Cullinan Therapeutics (NASDAQ: CGEM) anticipates a catalyst-rich 2026, driven by key advancements in its CLN-978 and CLN-049 programs. The company expects Q2 data for CLN-978, a T-cell engager for lupus and rheumatoid arthritis, focusing on B-cell depletion and safety. Additionally, CLN-049 for AML received FDA Fast Track designation, with plans for dose expansion and a Phase II study targeting 2027, supported by a strong cash position of over $430 million into 2029.
